Press Release: August 2, 2000

WR Hambrecht + Co Initiates Coverage of Allscripts (MDRX) with a Buy Rating and a Target of $38

Leading provider of wireless handheld solutions for doctors

San Francisco, CA, August 2, 2000—WR Hambrecht + Co today initiated research coverage on Allscripts (MDRX) with a buy rating and a price target of $38. WR Hambrecht + Co’s eHealth analyst Josh Fisher cited Allscript’s substantial market opportunity, strategic partnerships, and leadership position as key reasons for the rating. WR Hambrecht + Co offers all its research reports free and real-time at www.wrhambrecht.com.

“It’s still early in Allscript’s grand scheme but the potential is huge. These wireless products should make doctors more efficient, better informed, and ultimately lead to increased income for doctors and better care for patients. In our opinion, the total market size of the handheld electronic prescription market is greater than $2.5 billion, and as Allscripts introduces new applications, such as charge capture, its market opportunity should significantly expand,” Fisher said.

Fisher projects Allscript’s total revenues will reach $57 million in 2000 and $108 million in 2001, up from $27.5 million in 1999.

Allscripts, Inc. provides physicians with Internet and client/server medication management solutions designed to improve the quality and cost effectiveness of pharmaceutical healthcare.